What Is Agentic AI? (And Why Chatbots Are Just the Beginning)

When most people think about AI in the enterprise, they think about chatbots. They think about a text interface where you type a question and receive an answer — useful, certainly, and in many cases genuinely valuable. But chatbots represent the earliest, most limited expression of what AI can do. They are reactive. They respond when prompted. They do not plan, do not take initiative, do not execute multi-step workflows, and do not learn from the outcomes of their actions over time.

Agentic AI is categorically different. An agentic AI system is one that can perceive its environment, set goals, create and execute plans, use tools, and take sequences of actions in pursuit of those goals — all with a degree of autonomy that enables meaningful work to be done with minimal human direction at each step. Where a chatbot answers a question about regulatory submission requirements, an agentic AI system can read the applicable guidance documents, retrieve the relevant data from internal systems, draft the submission content, perform consistency checks, flag issues for human review, and track the submission through the approval workflow — without being hand-held through each step.

The technical architecture that enables this capability is worth understanding at a conceptual level, even for non-technical readers, because it explains why agentic AI is qualitatively different from previous AI generations. Agentic systems are built around a core reasoning engine — typically a large language model — that has been extended with four critical capabilities:

  • Tool use: The ability to call external functions, query databases, access APIs, run code, read documents, and interact with external systems
  • Memory: Both short-term working memory within a task and longer-term memory that persists across interactions, allowing the agent to accumulate context and learn from experience
  • Planning: The ability to decompose complex goals into sequences of subtasks, reason about dependencies between tasks, and adapt the plan as new information becomes available
  • Multi-agent coordination: The ability to orchestrate multiple specialized agents working in parallel, where each agent handles a specific domain or task type and reports results back to a coordinating agent

When these capabilities are combined, something genuinely new emerges: an AI system that functions more like a skilled autonomous colleague than a sophisticated search tool. The implications for knowledge-intensive, process-heavy industries like pharma are profound — and they are already being realized in production deployments.

The Chatbot-to-Agent Spectrum

It is useful to think about the progression from chatbot to autonomous agent as a spectrum with five distinct capability levels. Understanding where a given AI deployment falls on this spectrum helps organizations set appropriate expectations, design appropriate oversight mechanisms, and plan for the governance requirements that different levels of autonomy require.

At Level 1, a simple chatbot responds to prompts with generated text based on its training. At Level 2, a retrieval-augmented system can access external documents and data sources to ground its responses in current, specific information. At Level 3, a tool-using AI can take actions — running queries, calling APIs, executing code, filling out forms — based on the instructions given to it. At Level 4, a goal-directed agent can take a complex goal, break it down into steps, execute those steps using available tools, and report completion with evidence. At Level 5, a fully autonomous multi-agent system can self-direct complex workflows, coordinate multiple specialized agents, make decisions within defined parameters, and operate continuously without step-by-step human instruction.

Most commercial AI assistants deployed in enterprise settings today operate at Level 2 or 3. The frontier of production agentic deployments is at Level 4, with Level 5 capabilities emerging in specific, well-bounded domains. The life sciences industry is seeing meaningful Level 4 deployments in regulatory submissions, pharmacovigilance signal detection, and clinical trial operations — and these deployments are delivering results that are difficult to dismiss.

Why Pharma Is the Perfect Environment for Agentic AI

It might seem counterintuitive that pharma — one of the most regulated, risk-averse industries in the world — would be a leading environment for agentic AI adoption. The 23% adoption rate in pharma/healthcare as of 2024 places the sector at or near the front of the enterprise adoption curve. Why?

The answer lies in the nature of pharmaceutical work. Pharma organizations are, in a fundamental sense, knowledge management operations wrapped around chemistry. The core activities of the industry — drug discovery, clinical trial management, regulatory submissions, pharmacovigilance, quality management — all involve intensive processing of large volumes of structured and unstructured information, complex multi-step workflows with defined rules and standards, decisions that must be documented and traceable, and coordination across large, specialized teams with distinct domain expertise.

These characteristics make pharma an ideal environment for agentic AI for three reasons:

High-value, high-volume information processing: Pharmaceutical organizations generate and must process extraordinary volumes of structured and unstructured data — clinical trial data, adverse event reports, scientific literature, regulatory guidance, manufacturing batch records, quality system documentation. Agentic AI excels at exactly the kind of complex, multi-step information synthesis that these workflows require.

Process-rich, rule-governed workflows: Pharmaceutical processes operate within defined regulatory frameworks that specify what steps must be taken, what data must be collected, what reviews must be performed, and what documentation must be produced. These rule-governed workflows are highly amenable to agentic automation — the rules that govern the process are exactly the constraints that can be encoded in an agentic system’s operating parameters.

Extremely high cost of slow execution: In pharma, time is not just money — it is patient access to medicines. The average cost of a clinical trial delay is measured in millions of dollars per day. The time from discovery to approval spans more than a decade. Any technology that can meaningfully accelerate these timelines has disproportionate value — and agentic AI is demonstrating the ability to deliver that acceleration in ways that traditional automation could not.

Six High-Impact Use Cases in Life Sciences

The following six use cases represent the areas where agentic AI is delivering demonstrable, material impact in life sciences organizations today. These are not speculative — they are drawn from production deployments and credible industry research across the sector.

Regulatory Affairs

Regulatory Submission Acceleration

Agentic AI systems can compress regulatory submission timelines from the traditional 6–18 months to under 2 months by autonomously compiling supporting data, drafting narrative sections, performing consistency checks across the submission package, and flagging gaps for human review. Multiple agents coordinate across clinical, chemistry, and pharmacology documentation streams simultaneously.

Clinical Operations

Clinical Trial Management and Optimization

Agentic systems in clinical trials perform real-time adverse event monitoring with automatic signal escalation, protocol deviation detection and reporting, enrollment rate forecasting with site-level recommendations, and patient eligibility screening across complex inclusion/exclusion criteria. The result is faster enrollment, fewer protocol deviations, and earlier safety signal detection.

Pharmacovigilance

Adverse Event Processing and Signal Detection

Agentic AI transforms pharmacovigilance by autonomously processing incoming adverse event reports, coding events using standardized medical dictionaries, performing literature surveillance for new safety signals, and generating periodic safety reports. Early adopters report 60–80% reduction in manual case processing time, enabling pharmacovigilance teams to focus on signal interpretation and risk communication.

R&D

Drug Discovery and R&D Acceleration

In research and development settings, agentic AI performs continuous literature monitoring with hypothesis generation, in silico molecular screening against target profiles, experimental design optimization, and synthesis of research findings across disparate data sources. The ability to process and synthesize scientific literature at a scale impossible for human researchers is enabling identification of novel research directions and compound candidates that would otherwise be missed.

Commercial Operations

Commercial Intelligence and Market Access

Agentic AI systems in commercial operations monitor competitive intelligence sources, payer policy changes, prescriber behavior patterns, and market access developments — synthesizing this information into actionable briefings, access strategy recommendations, and contracting guidance. The continuous, autonomous monitoring capability converts what was previously a periodic, resource-intensive activity into a continuous intelligence function.

Quality Operations

Quality Event Management and Trending

In quality operations, agentic AI performs continuous monitoring of manufacturing process data for out-of-trend conditions, automatic preliminary investigation using historical comparison data, CAPA recommendation generation based on root cause patterns, and regulatory submission preparation for quality events. Organizations deploying agentic quality AI report significant reductions in time-to-investigation and improvements in root cause identification accuracy.

The Regulatory Submission Use Case in Depth

The regulatory submission acceleration use case deserves particular attention because it illustrates both the scale of the opportunity and the sophistication of what agentic AI can achieve in practice. Traditional regulatory submission processes involve dozens of contributors across multiple functional areas, complex version control challenges, extensive manual consistency checking, and a review and finalization cycle that can extend for months. The process is document-intensive, coordination-intensive, and error-prone at scale.

An agentic submission system addresses this challenge by deploying a coordinating agent that maintains the overall submission structure and progress, supported by specialized sub-agents responsible for specific sections. The clinical data agent retrieves and synthesizes clinical study reports. The chemistry and manufacturing agent compiles CMC documentation from laboratory and manufacturing systems. The regulatory intelligence agent reviews guidance documents and previous agency feedback to ensure the submission addresses known agency concerns. A consistency-checking agent reviews the complete package for cross-references, data inconsistencies, and formatting issues.

The coordinating agent manages dependencies between sections — knowing, for example, that the clinical summary section cannot be finalized until the individual study reports are complete — and maintains a live status view that human reviewers can consult at any time. Human experts remain in the loop for judgment calls, scientific interpretation, and final approval, but the mechanical coordination work that previously consumed enormous human time is handled autonomously.

The results being reported in production deployments are not incremental. The compression of 6–18 month processes to under 2 months represents a step-change in operational capability that has profound implications for product launch timelines, competitive positioning, and — most importantly — patient access to new therapies.

The Architecture of an Agentic System in a Regulated Environment

For life sciences professionals thinking about how to implement agentic AI in their organizations, understanding the basic architectural elements of an agentic system is essential. The architecture informs the governance requirements, the validation approach, and the integration strategy — all of which look different for agentic systems than for traditional software.

Goal Input

Human defines objective, constraints, and success criteria for the agent

Planning

Orchestrator agent decomposes goal into subtasks, sequences steps, assigns agents

Tool Execution

Agents call APIs, query databases, read documents, run computations

Synthesis

Results aggregated, validated, and assembled into coherent output

Human Review

Output reviewed, approved, or returned for revision at defined checkpoints

Action & Log

Approved outputs executed; complete audit trail written to GxP-compliant log

Core Architectural Components

The Orchestrator Agent: The central coordinating intelligence of the system. The orchestrator receives high-level goals, decomposes them into executable subtasks, assigns work to specialized sub-agents, manages dependencies between tasks, and aggregates results into coherent outputs. In a regulated pharmaceutical context, the orchestrator must maintain a complete, auditable record of its planning and execution decisions.

Specialized Sub-Agents: Individual agents with specific capabilities — a document analysis agent, a data retrieval agent, a writing agent, a consistency-checking agent. The modularity of multi-agent architectures is one of their key advantages in regulated environments: each agent’s function is bounded and testable, its inputs and outputs are defined, and its validation scope is limited to its specific capability domain.

Tool Registry: The set of external tools and systems that agents can access — database query interfaces, API connectors, document processing tools, code execution environments. In a GxP-regulated environment, tool access must be controlled, logged, and validated. The tool registry defines the boundaries of the agent’s operating environment.

Memory Architecture: Agentic systems require both working memory (context about the current task) and longer-term memory (persistent knowledge about the organization’s data, preferences, and history). In regulated environments, memory systems require particular attention: what information is retained, for how long, by whom, and under what access controls must all be defined and controlled.

Human-in-the-Loop Integration Points: Well-designed agentic systems define explicit checkpoints where human review and approval are required before the system proceeds. These checkpoints are not just governance accommodations — they are architectural features that enable escalation, override, and course correction. The placement and design of human-in-the-loop integration points is one of the most important design decisions in building compliant agentic systems for regulated industries.

Governance, Validation, and Trust: Getting It Right

Let me be direct about something: the governance and validation challenges of agentic AI in regulated environments are real, and taking them seriously is essential. The enthusiasm I feel about what agentic AI can achieve for life sciences organizations is matched by my conviction that getting the governance right is what makes that achievement sustainable and trustworthy.

Agentic AI in GxP-regulated environments raises governance challenges that are genuinely novel — not because AI is uniquely dangerous, but because autonomous multi-step systems do not fit cleanly into the validation frameworks designed for deterministic software. The traditional IQ/OQ/PQ approach validates a system that behaves the same way every time it receives the same input. Agentic systems, by design, adapt their behavior to context, handle novel situations, and make decisions that were not explicitly programmed. This is precisely what makes them valuable — and precisely what requires a different validation approach.

GxP and Validation Considerations for Regulated Environments: Agentic AI deployments in GxP-regulated workflows (manufacturing, laboratory operations, clinical trials, regulatory submissions) require a validation approach that extends beyond traditional software validation. Key requirements include: (1) Definition of the intended use and operational boundaries of the agentic system, including explicit documentation of what decisions the system can make autonomously and what requires human approval; (2) Risk-based validation testing that covers not just expected behavior but boundary conditions, edge cases, and failure modes specific to AI systems; (3) Complete audit trail requirements that capture not just what the system did but the reasoning and tool calls that led to each action; (4) Change management procedures that address model updates, prompt modifications, and tool additions as changes to the validated state; (5) Ongoing performance monitoring with defined drift detection thresholds that trigger revalidation or review. Consult with your regulatory counsel and validation specialists before deploying agentic AI in any GxP-critical workflow.

A Risk-Based Approach to Agentic AI Governance

The most practical approach to governing agentic AI in life sciences is a risk-based framework that calibrates the governance requirements to the criticality of the workflow and the degree of autonomous decision-making involved. The framework should address four dimensions:

Decision criticality: What is the consequence of an incorrect decision by the agentic system? Decisions that directly affect patient safety, product quality, or regulatory compliance require the highest levels of oversight. Decisions that affect operational efficiency but have limited safety or quality implications allow for lighter oversight.

Reversibility: Can the consequences of an incorrect decision be reversed? Actions that are easily reversed — drafting a document that will be reviewed before use — permit more autonomy than actions that are difficult or impossible to reverse, such as submitting a regulatory document or releasing a batch for distribution.

Transparency: Can the reasoning behind the agentic system’s decisions be understood and audited? Systems that provide interpretable reasoning trails are more amenable to governance than black-box systems that produce outputs without explanations.

Human override accessibility: How easily can human operators understand what the system is doing and intervene if needed? Systems with intuitive monitoring interfaces and clear override mechanisms are fundamentally safer than systems that require deep technical expertise to monitor and control.

Building Institutional Trust

The most durable governance outcome is not a compliance checklist — it is institutional trust in the agentic system, built through evidence of consistent, correct performance over time. Organizations that build this trust systematically — starting with bounded, lower-risk use cases, measuring performance rigorously, documenting the evidence base, and expanding autonomy incrementally as the evidence accumulates — create a compelling internal story about the reliability and value of agentic AI that accelerates further adoption.

Organizations that try to deploy agentic AI in the most ambitious, highest-risk workflows immediately, without the evidence base to support that level of trust, create exactly the kind of high-profile failures that set back institutional AI confidence for years.

Where to Start: A Readiness Framework for Life Sciences Organizations

If you have been following the argument of this article and find yourself thinking “this is compelling, but where do we actually begin?” — this section is for you. The readiness framework below is designed for life sciences organizations at any stage of AI maturity, from those that have deployed chatbots and want to move to agentic capabilities, to those that are starting the AI journey fresh and want to start it at the right level.

Level 1 — Chatbot Single-turn Q&A; no tool use; no memory; human provides all context; useful but limited
Level 2 — RAG-Enhanced Retrieval-augmented generation; accesses internal documents; grounded responses; still single-turn
Level 3 — Tool-Using Agent Queries databases, calls APIs, executes code; multi-step within session; human approval on outputs
Level 4 — Goal-Directed Agent Autonomous multi-step execution; orchestrates sub-tasks; defined human checkpoints; validated workflows
Level 5 — Autonomous Multi-Agent Continuous autonomous operation; multi-agent coordination; self-monitoring; strategic AI capability

The readiness assessment has four dimensions that each organization should evaluate honestly before deciding where to start and how fast to move:

1

Data Readiness

Agentic AI systems are only as effective as the data they can access. Assess the quality, accessibility, and structure of the data sources that would be relevant to your target use cases. Are clinical data, regulatory documentation, quality records, and research data accessible through APIs or queryable databases, or are they locked in legacy systems, unstructured formats, or siloed repositories? Organizations with mature data architecture and accessible data assets will achieve faster time-to-value from agentic deployments. Those with significant data accessibility challenges should treat data modernization as a prerequisite investment.

2

Process Readiness

Identify specific, high-value workflows that are candidates for agentic automation. The best initial candidates share a profile: they are high-volume, time-consuming, rule-governed, and currently performed by skilled humans who would be more valuable doing higher-order work. They have clear inputs and outputs that can be defined. They have tolerance for a human review step at the output stage. Regulatory submission preparation, adverse event coding and processing, literature surveillance, and protocol deviation review are common high-value starting points. Avoid selecting use cases that require nuanced scientific judgment as the primary activity — agentic AI excels at process and synthesis, not at replacing deep scientific expertise.

3

Governance Readiness

Before deploying agentic AI in any workflow, establish the governance foundation. This means defining who owns the agentic system (a business owner, not just IT), establishing the validation approach for the specific use case, defining the human-in-the-loop checkpoints and override procedures, and creating the audit trail requirements. Organizations that have invested in EU AI Act compliance or FDA’s AI guidance frameworks will find this work partially done. Those without existing AI governance infrastructure should treat this as the first investment, not an afterthought.

4

Talent and Culture Readiness

Agentic AI changes how work gets done, not just how fast it gets done. The people working with agentic systems need a new kind of skill: the ability to define goals clearly, evaluate complex AI outputs critically, and intervene effectively when the system’s reasoning goes wrong. This is not the same skill as using a software application. Invest in building this capability early — through hands-on experience with agentic tools, through explicit training on AI output evaluation, and through a culture that encourages experimentation and tolerates informed failure. The organizations that build agentic AI fluency across their workforces will have a compounding advantage that is very difficult for late movers to replicate.

Sakara Digital Perspective on Getting Started: The single most effective thing we see organizations do to accelerate agentic AI adoption is to identify one high-value use case, assign a senior sponsor who genuinely cares about the outcome, and build a small cross-functional team (2–3 people with domain expertise + 1 AI specialist) to prototype it in 60–90 days. The prototype does not have to be production-ready or fully validated. Its job is to demonstrate value, build intuition about what agentic AI can and cannot do, and create organizational momentum. The organizations that spend six months selecting a platform and building a governance framework before anyone has touched the technology consistently move slower than those that learn by doing — in a controlled, low-risk context. Start small, demonstrate value, build on success.

The FDA Signal: Regulatory Agencies Are Already There

One of the most compelling signals that agentic AI has crossed from emerging technology to operational reality in life sciences is the FDA’s own deployment. The ELSA platform, launched in June 2025, uses agentic AI to continuously analyze inspection data, adverse event patterns, warning letter histories, and facility compliance records — generating risk scores and inspection prioritization recommendations that direct FDA inspection resources toward high-risk facilities. The FDA did not deploy this technology as an experiment. It deployed it because it works.

The implication for life sciences organizations is significant: your regulator is using agentic AI to analyze your compliance posture. Organizations that are still debating whether agentic AI is ready for regulated environments are debating a question that the FDA has already answered with its own production deployment. The technology is ready. The question is whether your organization will use it to improve your compliance posture — or whether you will be the organization being analyzed by someone else’s agentic AI.

Conclusion: The Agentic Future Is Already Here

I want to close this article the way it opened: with genuine enthusiasm about what is happening right now in life sciences AI, and a direct invitation to be part of it.

The data points are remarkable. Regulatory submissions compressed from eighteen months to eight weeks. Pharmacovigilance case processing that used to require hours of expert analyst time handled in minutes. Clinical trial enrollment managed with real-time optimization that would have required a dedicated operational infrastructure to approximate manually. These are not projections — they are current results from organizations that decided to move forward rather than wait for perfect conditions.

The life sciences industry exists to develop and deliver medicines and medical technologies that improve and extend human lives. Every month saved in a regulatory submission timeline is a month of earlier patient access. Every adverse event signal detected earlier through agentic pharmacovigilance is a safety risk identified before it causes additional harm. The stakes of this work are not abstract — they are patient lives and outcomes that depend on the pace and quality of the work we do.

Agentic AI is not a productivity tool layered on top of existing work. It is a fundamental expansion of what is possible — an amplification of human expertise that enables the same talented professionals to accomplish work at a scale and speed that was not previously achievable. The future of pharmaceutical development, regulatory science, and life sciences operations will be built by humans and agentic AI working together, each contributing what they do best.

That future is not on the horizon. It has already begun for the organizations willing to pursue it. The invitation stands.